Syntrix Biosystems, Inc.
- Country
- πΊπΈUnited States
- Ownership
- Private
- Established
- 2001-11-27
- Employees
- 1
- Market Cap
- -
- Website
- http://www.syntrixbio.com
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)β’ Click on a phase to view related trials
Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Syntrix Biosystems, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT06228053
- Locations
- πΊπΈ
University of California, Los Angeles, Los Angeles, California, United States
πΊπΈUniversity of California, San Francisco, San Francisco, California, United States
πΊπΈUniversity of Michigan, Ann Arbor, Michigan, United States
A Randomized Study Investigating Oral Desmetramadol Dose Proportionality and Food Effect In Normal Human Subjects
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Syntrix Biosystems, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04683926
- Locations
- πΊπΈ
Celerion, Lincoln, Nebraska, United States
Study of SX-682 Alone and in Combination with Oral or Intravenous Decitabine in Subjects with Myelodysplastic Syndrome
- First Posted Date
- 2020-01-28
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Syntrix Biosystems, Inc.
- Target Recruit Count
- 151
- Registration Number
- NCT04245397
- Locations
- πΊπΈ
Mayo Clinic, Jacksonville, Florida, United States
πΊπΈUniversity of Miami, Miami, Florida, United States
πΊπΈAdventHealth Medical Group & Bone Marrow Transplant at Orlando, Orlando, Florida, United States
Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy
- Conditions
- Pain, ChronicDiabetic NeuropathiesNeuropathic Pain
- Interventions
- Drug: Omnitram Oral TabletDrug: Placebo Oral Tablet
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- Syntrix Biosystems, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT03664921
- Locations
- πΊπΈ
Orange County Research Institute, Anaheim, California, United States
πΊπΈCore Healthcare Group, Cerritos, California, United States
πΊπΈSt. Louis Clinical Trials, Saint Louis, Missouri, United States
Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis
- Conditions
- Psoriasis
- Interventions
- Drug: Placebo oral capsuleDrug: LD-Aminopterin oral capsule
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Syntrix Biosystems, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT03431974
- Locations
- πΊπΈ
Spectrum Dermatology, Scottsdale, Arizona, United States
πΊπΈDermatology Associates of Seattle, Seattle, Washington, United States
πΊπΈPremier Clinical Research, Spokane, Washington, United States
- Prev
- 1
- 2
- Next